IGFBP1 Human, HEK
HEK293 Cells.
Sterile Filtered colorless solution.
Description
IGFBP1 Human Recombinant is a single, glycosylated, polypeptide chain (26-259 a.a) containing a total of 234 amino acids, having a molecular mass of 25.2 kDa.
IGFBP1 is purified by proprietary chromatographic techniques.
Product Specs
Recombinant human IGFBP1 is a single polypeptide chain with glycosylation. It consists of 234 amino acids (26-259 a.a) and has a molecular weight of 25.2 kDa. The purification of IGFBP1 is achieved through proprietary chromatographic techniques.
A clear, colorless solution that has been sterile filtered.
The IGFBP1 solution is provided at a concentration of 0.5 mg/ml and contains 10% glycerol in phosphate-buffered saline (pH 7.4).
For short-term storage (up to 2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein (HSA or BSA) at a concentration of 0.1% is advised for long-term storage. Repeated freezing and thawing should be avoided.
The ED50, determined by measuring the inhibition of MCF-7 human breast cancer cell proliferation in the presence of human IGF-1, is less than or equal to 3 µg/ml.
HEK293 Cells.
APWQCAPCSA EKLALCPPVS ASCSEVTRSA GCGCCPMCAL PLGAACGVAT ARCARGLSCR ALPGEQQPLH ALTRGQGACV QESDASAPHA AEAGSPESPE STEITEEELL DNFHLMAPSE EDHSILWDAI STYDGSKALH VTNIKKWKEP CRIELYRVVE SLAKAQETSG EEISKFYLPN CNKNGFYHSR QCETSMDGEA GLCWCVYPWN GKRIPGSPEI RGDPNCQIYF NVQN.
Product Science Overview
Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) is a member of the insulin-like growth factor binding protein family. This family of proteins plays a crucial role in regulating the activity of insulin-like growth factors (IGFs), which are essential for growth and development. IGFBP-1 is known for its ability to bind both insulin-like growth factor I and insulin-like growth factor II, thereby modulating their biological activities .
IGFBP-1 is characterized by the presence of an insulin-like growth factor binding domain and a thyroglobulin type-I domain . The protein is composed of 234 amino acids and has a molecular weight ranging from 30 to 35 kilodaltons . It is primarily expressed in the liver and circulates in the plasma, where it binds to insulin-like growth factors, extending their half-life and regulating their interaction with receptors .
IGFBP-1 serves multiple functions in the body:
- Regulation of IGF Activity: By binding to insulin-like growth factors, IGFBP-1 can either inhibit or stimulate their growth-promoting effects. This modulation is crucial for fine-tuning the signaling pathways mediated by insulin-like growth factors .
- Cell Migration: IGFBP-1 promotes cell migration, which is vital for various physiological processes, including wound healing and tissue regeneration .
- Signal Transduction: The binding of IGFBP-1 to insulin-like growth factors alters their interaction with receptors, thereby influencing downstream signaling pathways .
The recombinant form of IGFBP-1, produced in Human Embryonic Kidney (HEK) cells, is used extensively in research and therapeutic applications. The recombinant protein retains the functional properties of the native protein, making it a valuable tool for studying the biological roles of IGFBP-1 and its interactions with insulin-like growth factors .
Recombinant IGFBP-1 is utilized in various research studies to investigate its role in different physiological and pathological conditions. Some of the key applications include:
- Cancer Research: IGFBP-1 is studied for its potential role in cancer progression and metastasis. By modulating the activity of insulin-like growth factors, IGFBP-1 can influence tumor growth and cell migration .
- Metabolic Disorders: Research on IGFBP-1 helps in understanding its involvement in metabolic disorders such as diabetes and obesity. The protein’s ability to regulate insulin-like growth factor activity makes it a critical factor in metabolic homeostasis .
- Therapeutic Development: Recombinant IGFBP-1 is explored for its potential therapeutic applications, including the development of treatments for conditions associated with abnormal insulin-like growth factor signaling .
